Athira Pharma, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Perceptive Advisors LLC, along with related entities and Joseph Edelman, reported the acquisition of stock options for LeonaBio, Inc. (LONA) on April 9, 2026.
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund Ltd., reported a stock option grant for 28,000 shares of LionaBio, Inc. common stock.
LeonaBio, Inc. reports that Director Fred Callori was granted stock options for 2,333 shares.
LeonaBio, Inc. reports a Form 4 filing detailing stock option grants to Director Natalie C. Holles.
LeonaBio, Inc. director Peter B. Silverman acquired stock options as part of the company's Outside Director Compensation Policy.
LeonaBio, Inc. reports that Director Michael A. Panzara acquired 28,000 stock options under the company's Outside Director Compensation Policy.
LeonaBio, Inc. director Kelly A. Romano acquired 28,000 stock options with an exercise price of $8.35, vesting over time.
Director Joseph Edelman acquired stock options for 28,000 shares of LeonaBio, Inc. under the company's Outside Director Compensation Policy.
LeonaBio, Inc. reports the grant of stock options to Director James A. Johnson, with vesting contingent on specific future dates.
LeonaBio, Inc. director Barbara Kosacz acquired 28,000 stock options with an exercise price of $8.35, vesting on June 23, 2027, or the day before the next annual meeting.
LeonaBio, Inc. director Grant Pickering was granted stock options to acquire 28,000 shares of common stock at an exercise price of $8.35.
Director Natalie C. Holles was granted 56,000 stock options in LeonaBio, Inc. as part of the company's 2026 Equity Incentive Plan.
Director Peter B. Silverman was granted 56,000 stock options in LeonaBio, Inc. as part of the company's 2026 Equity Incentive Plan.
Director Fred Callori was granted 56,000 stock options in LeonaBio, Inc. as part of the company's 2026 Equity Incentive Plan.
LeonaBio, Inc. director Michael A. Panzara acquired 28,000 stock options with an exercise price of $9.54, vesting over 24 months.
LeonaBio, Inc. reports that Chief Scientific Officer Kevin Church acquired 300,000 stock options.
LeonaBio, Inc. Director Barbara Kosacz acquired 28,000 stock options with an exercise price of $9.54, vesting over 24 months.
LeonaBio, Inc. director Grant Pickering acquired 28,000 stock options with an exercise price of $9.54, vesting over 24 months.
LeonaBio, Inc. Director Kelly A. Romano reported the acquisition of 28,000 stock options with an exercise price of $9.54, vesting over 24 months.
LeonaBio, Inc. director James A. Johnson acquired 28,000 stock options with an exercise price of $9.54, vesting over 24 months.
LeonaBio, Inc. reports that Director Joseph Edelman acquired stock options for 28,000 shares.
Javier San Martin, Chief Medical Officer of LeonaBio, Inc., has acquired 350,000 stock options with an exercise price of $9.54.
Director John M. Fluke Jr. acquired 28,000 stock options in LeonaBio, Inc. on April 9, 2026, as detailed in a Form 4 filing.
Mark Worthington, General Counsel and CCO of LeonaBio, Inc., acquired 300,000 stock options with an exercise price of $9.54.
LeonaBio, Inc. reports that Chief Financial Officer Robert Renninger acquired 300,000 stock options.
LeonaBio, Inc. reports a significant stock option grant to President and CEO Mark James Litton, with vesting over four years.
LeonaBio, Inc.'s President and CEO, Mark James Litton, reported the vesting of 22,254 restricted stock units and a subsequent non-discretionary sale of 5,156 shares to cover tax obligations.
LeonaBio's Chief Financial Officer, Robert Renninger, acquired 3,900 shares upon RSU vesting and subsequently sold 906 shares to cover tax obligations.
LeonaBio's General Counsel, Mark Worthington, sold 1,328 shares of common stock to cover tax obligations following the vesting of 5,726 restricted stock units.
LeonaBio's Chief Scientific Officer, Kevin Church, sold a portion of his common stock to cover tax obligations following the vesting of restricted stock units.